

Long-Acting Monoclonal Antibodies-Global Market Status & Trend Report 2016-2026 Top 20 Countries Data

<https://marketpublishers.com/r/L3DBBB1F6192EN.html>

Date: December 2021

Pages: 142

Price: US\$ 3,680.00 (Single User License)

ID: L3DBBB1F6192EN

Abstracts

Report Summary

Long-Acting Monoclonal Antibodies-Global Market Status & Trend Report 2016-2026 Top 20 Countries Data offers a comprehensive analysis on Long-Acting Monoclonal Antibodies industry, standing on the readers' perspective, delivering detailed market data in Global major 20 countries and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Worldwide and Top 20 Countries Market Size of Long-Acting Monoclonal Antibodies 2016-2021, and development forecast 2022-2026

Main manufacturers/suppliers of Long-Acting Monoclonal Antibodies worldwide and market share by regions, with company and product introduction, position in the Long-Acting Monoclonal Antibodies market

Market status and development trend of Long-Acting Monoclonal Antibodies by types and applications

Cost and profit status of Long-Acting Monoclonal Antibodies, and marketing status

Market growth drivers and challenges Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Ammonium Long-Acting Monoclonal Antibodies market in 2020. COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets. The outbreak of COVID-19 has brought

effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future. This report also analyses the impact of Coronavirus COVID-19 on the Long-Acting Monoclonal Antibodies industry.

The report segments the global Long-Acting Monoclonal Antibodies market as:

Global Long-Acting Monoclonal Antibodies Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2016-2026):

North America (United States, Canada and Mexico)

Europe (Germany, UK, France, Italy, Russia, Spain and Benelux)

Asia Pacific (China, Japan, India, Southeast Asia and Australia)

Latin America (Brazil, Argentina and Colombia)

Middle East and Africa

Global Long-Acting Monoclonal Antibodies Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2016-2026):

Murine Source

Chimeric Source

Human Source

Global Long-Acting Monoclonal Antibodies Market: Application Segment Analysis (Consumption Volume and Market Share 2016-2026; Downstream Customers and Market Analysis)

Cancer

Autoimmune Diseases

Inflammatory Diseases

Infectious Diseases

Others

Global Long-Acting Monoclonal Antibodies Market: Manufacturers Segment Analysis (Company and Product introduction, Long-Acting Monoclonal Antibodies Sales Volume, Revenue, Price and Gross Margin):

Eli Lilly

Abbott Laboratories

AstraZeneca

Amgen
Bayer AG
Johnson & Johnson
Pfizer
GlaxoSmithKline
Merck
Novartis

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF LONG-ACTING MONOCLONAL ANTIBODIES

- 1.1 Definition of Long-Acting Monoclonal Antibodies in This Report
- 1.2 Commercial Types of Long-Acting Monoclonal Antibodies
 - 1.2.1 Murine Source
 - 1.2.2 Chimeric Source
 - 1.2.3 Human Source
- 1.3 Downstream Application of Long-Acting Monoclonal Antibodies
 - 1.3.1 Cancer
 - 1.3.2 Autoimmune Diseases
 - 1.3.3 Inflammatory Diseases
 - 1.3.4 Infectious Diseases
 - 1.3.5 Others
- 1.4 Development History of Long-Acting Monoclonal Antibodies
- 1.5 Market Status and Trend of Long-Acting Monoclonal Antibodies 2016-2026
 - 1.5.1 Global Long-Acting Monoclonal Antibodies Market Status and Trend 2016-2026
 - 1.5.2 Regional Long-Acting Monoclonal Antibodies Market Status and Trend 2016-2026

CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Development of Long-Acting Monoclonal Antibodies 2016-2021
- 2.2 Sales Market of Long-Acting Monoclonal Antibodies by Regions
 - 2.2.1 Sales Volume of Long-Acting Monoclonal Antibodies by Regions
 - 2.2.2 Sales Value of Long-Acting Monoclonal Antibodies by Regions
- 2.3 Production Market of Long-Acting Monoclonal Antibodies by Regions
- 2.4 Global Market Forecast of Long-Acting Monoclonal Antibodies 2022-2026
 - 2.4.1 Global Market Forecast of Long-Acting Monoclonal Antibodies 2022-2026
 - 2.4.2 Market Forecast of Long-Acting Monoclonal Antibodies by Regions 2022-2026

CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES

- 3.1 Sales Volume of Long-Acting Monoclonal Antibodies by Types
- 3.2 Sales Value of Long-Acting Monoclonal Antibodies by Types
- 3.3 Market Forecast of Long-Acting Monoclonal Antibodies by Types

CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM

INDUSTRY

4.1 Global Sales Volume of Long-Acting Monoclonal Antibodies by Downstream Industry

4.2 Global Market Forecast of Long-Acting Monoclonal Antibodies by Downstream Industry

CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

5.1 North America Long-Acting Monoclonal Antibodies Market Status by Countries

5.1.1 North America Long-Acting Monoclonal Antibodies Sales by Countries (2016-2021)

5.1.2 North America Long-Acting Monoclonal Antibodies Revenue by Countries (2016-2021)

5.1.3 United States Long-Acting Monoclonal Antibodies Market Status (2016-2021)

5.1.4 Canada Long-Acting Monoclonal Antibodies Market Status (2016-2021)

5.1.5 Mexico Long-Acting Monoclonal Antibodies Market Status (2016-2021)

5.2 North America Long-Acting Monoclonal Antibodies Market Status by Manufacturers

5.3 North America Long-Acting Monoclonal Antibodies Market Status by Type (2016-2021)

5.3.1 North America Long-Acting Monoclonal Antibodies Sales by Type (2016-2021)

5.3.2 North America Long-Acting Monoclonal Antibodies Revenue by Type (2016-2021)

5.4 North America Long-Acting Monoclonal Antibodies Market Status by Downstream Industry (2016-2021)

CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

6.1 Europe Long-Acting Monoclonal Antibodies Market Status by Countries

6.1.1 Europe Long-Acting Monoclonal Antibodies Sales by Countries (2016-2021)

6.1.2 Europe Long-Acting Monoclonal Antibodies Revenue by Countries (2016-2021)

6.1.3 Germany Long-Acting Monoclonal Antibodies Market Status (2016-2021)

6.1.4 UK Long-Acting Monoclonal Antibodies Market Status (2016-2021)

6.1.5 France Long-Acting Monoclonal Antibodies Market Status (2016-2021)

6.1.6 Italy Long-Acting Monoclonal Antibodies Market Status (2016-2021)

6.1.7 Russia Long-Acting Monoclonal Antibodies Market Status (2016-2021)

6.1.8 Spain Long-Acting Monoclonal Antibodies Market Status (2016-2021)

- 6.1.9 Benelux Long-Acting Monoclonal Antibodies Market Status (2016-2021)
- 6.2 Europe Long-Acting Monoclonal Antibodies Market Status by Manufacturers
- 6.3 Europe Long-Acting Monoclonal Antibodies Market Status by Type (2016-2021)
 - 6.3.1 Europe Long-Acting Monoclonal Antibodies Sales by Type (2016-2021)
 - 6.3.2 Europe Long-Acting Monoclonal Antibodies Revenue by Type (2016-2021)
- 6.4 Europe Long-Acting Monoclonal Antibodies Market Status by Downstream Industry (2016-2021)

CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

- 7.1 Asia Pacific Long-Acting Monoclonal Antibodies Market Status by Countries
 - 7.1.1 Asia Pacific Long-Acting Monoclonal Antibodies Sales by Countries (2016-2021)
 - 7.1.2 Asia Pacific Long-Acting Monoclonal Antibodies Revenue by Countries (2016-2021)
 - 7.1.3 China Long-Acting Monoclonal Antibodies Market Status (2016-2021)
 - 7.1.4 Japan Long-Acting Monoclonal Antibodies Market Status (2016-2021)
 - 7.1.5 India Long-Acting Monoclonal Antibodies Market Status (2016-2021)
 - 7.1.6 Southeast Asia Long-Acting Monoclonal Antibodies Market Status (2016-2021)
 - 7.1.7 Australia Long-Acting Monoclonal Antibodies Market Status (2016-2021)
- 7.2 Asia Pacific Long-Acting Monoclonal Antibodies Market Status by Manufacturers
- 7.3 Asia Pacific Long-Acting Monoclonal Antibodies Market Status by Type (2016-2021)
 - 7.3.1 Asia Pacific Long-Acting Monoclonal Antibodies Sales by Type (2016-2021)
 - 7.3.2 Asia Pacific Long-Acting Monoclonal Antibodies Revenue by Type (2016-2021)
- 7.4 Asia Pacific Long-Acting Monoclonal Antibodies Market Status by Downstream Industry (2016-2021)

CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

- 8.1 Latin America Long-Acting Monoclonal Antibodies Market Status by Countries
 - 8.1.1 Latin America Long-Acting Monoclonal Antibodies Sales by Countries (2016-2021)
 - 8.1.2 Latin America Long-Acting Monoclonal Antibodies Revenue by Countries (2016-2021)
 - 8.1.3 Brazil Long-Acting Monoclonal Antibodies Market Status (2016-2021)
 - 8.1.4 Argentina Long-Acting Monoclonal Antibodies Market Status (2016-2021)
 - 8.1.5 Colombia Long-Acting Monoclonal Antibodies Market Status (2016-2021)
- 8.2 Latin America Long-Acting Monoclonal Antibodies Market Status by Manufacturers

8.3 Latin America Long-Acting Monoclonal Antibodies Market Status by Type (2016-2021)

8.3.1 Latin America Long-Acting Monoclonal Antibodies Sales by Type (2016-2021)

8.3.2 Latin America Long-Acting Monoclonal Antibodies Revenue by Type (2016-2021)

8.4 Latin America Long-Acting Monoclonal Antibodies Market Status by Downstream Industry (2016-2021)

CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

9.1 Middle East and Africa Long-Acting Monoclonal Antibodies Market Status by Countries

9.1.1 Middle East and Africa Long-Acting Monoclonal Antibodies Sales by Countries (2016-2021)

9.1.2 Middle East and Africa Long-Acting Monoclonal Antibodies Revenue by Countries (2016-2021)

9.1.3 Middle East Long-Acting Monoclonal Antibodies Market Status (2016-2021)

9.1.4 Africa Long-Acting Monoclonal Antibodies Market Status (2016-2021)

9.2 Middle East and Africa Long-Acting Monoclonal Antibodies Market Status by Manufacturers

9.3 Middle East and Africa Long-Acting Monoclonal Antibodies Market Status by Type (2016-2021)

9.3.1 Middle East and Africa Long-Acting Monoclonal Antibodies Sales by Type (2016-2021)

9.3.2 Middle East and Africa Long-Acting Monoclonal Antibodies Revenue by Type (2016-2021)

9.4 Middle East and Africa Long-Acting Monoclonal Antibodies Market Status by Downstream Industry (2016-2021)

CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF LONG-ACTING MONOCLONAL ANTIBODIES

10.1 Global Economy Situation and Trend Overview

10.2 Long-Acting Monoclonal Antibodies Downstream Industry Situation and Trend Overview

CHAPTER 11 LONG-ACTING MONOCLONAL ANTIBODIES MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS

- 11.1 Production Volume of Long-Acting Monoclonal Antibodies by Major Manufacturers
- 11.2 Production Value of Long-Acting Monoclonal Antibodies by Major Manufacturers
- 11.3 Basic Information of Long-Acting Monoclonal Antibodies by Major Manufacturers
 - 11.3.1 Headquarters Location and Established Time of Long-Acting Monoclonal Antibodies Major Manufacturer
 - 11.3.2 Employees and Revenue Level of Long-Acting Monoclonal Antibodies Major Manufacturer
- 11.4 Market Competition News and Trend
 - 11.4.1 Merger, Consolidation or Acquisition News
 - 11.4.2 Investment or Disinvestment News
 - 11.4.3 New Product Development and Launch

CHAPTER 12 LONG-ACTING MONOCLONAL ANTIBODIES MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

- 12.1 Eli Lilly
 - 12.1.1 Company profile
 - 12.1.2 Representative Long-Acting Monoclonal Antibodies Product
 - 12.1.3 Long-Acting Monoclonal Antibodies Sales, Revenue, Price and Gross Margin of Eli Lilly
- 12.2 Abbott Laboratories
 - 12.2.1 Company profile
 - 12.2.2 Representative Long-Acting Monoclonal Antibodies Product
 - 12.2.3 Long-Acting Monoclonal Antibodies Sales, Revenue, Price and Gross Margin of Abbott Laboratories
- 12.3 AstraZeneca
 - 12.3.1 Company profile
 - 12.3.2 Representative Long-Acting Monoclonal Antibodies Product
 - 12.3.3 Long-Acting Monoclonal Antibodies Sales, Revenue, Price and Gross Margin of AstraZeneca
- 12.4 Amgen
 - 12.4.1 Company profile
 - 12.4.2 Representative Long-Acting Monoclonal Antibodies Product
 - 12.4.3 Long-Acting Monoclonal Antibodies Sales, Revenue, Price and Gross Margin of Amgen
- 12.5 Bayer AG
 - 12.5.1 Company profile
 - 12.5.2 Representative Long-Acting Monoclonal Antibodies Product
 - 12.5.3 Long-Acting Monoclonal Antibodies Sales, Revenue, Price and Gross Margin of

Bayer AG

12.6 Johnson & Johnson

12.6.1 Company profile

12.6.2 Representative Long-Acting Monoclonal Antibodies Product

12.6.3 Long-Acting Monoclonal Antibodies Sales, Revenue, Price and Gross Margin of Johnson & Johnson

12.7 Pfizer

12.7.1 Company profile

12.7.2 Representative Long-Acting Monoclonal Antibodies Product

12.7.3 Long-Acting Monoclonal Antibodies Sales, Revenue, Price and Gross Margin of Pfizer

12.8 GlaxoSmithKline

12.8.1 Company profile

12.8.2 Representative Long-Acting Monoclonal Antibodies Product

12.8.3 Long-Acting Monoclonal Antibodies Sales, Revenue, Price and Gross Margin of GlaxoSmithKline

12.9 Merck

12.9.1 Company profile

12.9.2 Representative Long-Acting Monoclonal Antibodies Product

12.9.3 Long-Acting Monoclonal Antibodies Sales, Revenue, Price and Gross Margin of Merck

12.10 Novartis

12.10.1 Company profile

12.10.2 Representative Long-Acting Monoclonal Antibodies Product

12.10.3 Long-Acting Monoclonal Antibodies Sales, Revenue, Price and Gross Margin of Novartis

CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF LONG-ACTING MONOCLONAL ANTIBODIES

13.1 Industry Chain of Long-Acting Monoclonal Antibodies

13.2 Upstream Market and Representative Companies Analysis

13.3 Downstream Market and Representative Companies Analysis

CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF LONG-ACTING MONOCLONAL ANTIBODIES

14.1 Cost Structure Analysis of Long-Acting Monoclonal Antibodies

14.2 Raw Materials Cost Analysis of Long-Acting Monoclonal Antibodies

14.3 Labor Cost Analysis of Long-Acting Monoclonal Antibodies

14.4 Manufacturing Expenses Analysis of Long-Acting Monoclonal Antibodies

CHAPTER 15 REPORT CONCLUSION

CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE

16.1 Methodology/Research Approach

16.1.1 Research Programs/Design

16.1.2 Market Size Estimation

16.1.3 Market Breakdown and Data Triangulation

16.2 Data Source

16.2.1 Secondary Sources

16.2.2 Primary Sources

16.3 Reference

I would like to order

Product name: Long-Acting Monoclonal Antibodies-Global Market Status & Trend Report 2016-2026 Top 20 Countries Data

Product link: <https://marketpublishers.com/r/L3DBBB1F6192EN.html>

Price: US\$ 3,680.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/L3DBBB1F6192EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

